ISSN 2581-6217

World Journal of Pharmaceutical Science & Technology

Journal homepage: www.wjpst.com

Review Article

COMPARATIVE ANALYSIS OF PHARMACOVIGILANCE METHODS AND RECENT DEVELOPMENTS

Mr. Prasad D. Rayte[1], Ms. Archana Gawade[2]

1. B.Pharm Scholar, MET BKC Institute Of Pharmacy, Nashik and Advance Diploma in Pharmacovigilance and clinical research Scholar from Elite institute of Pharma Skills Pune.
2. Managing Director, Elite Institute Of Pharma Skills, Pune

Address for correspondence:

Mr. Prasad D. Rayte B.Pharm Scholar, MET BKC Institute Of Pharmacy, Nashik and Advance Diploma Pharmacovigilance and clinical research Scholar from Elite institute of Pharma Skills Pune.

E-mail- prasadrayte366@gmail.com

Received: 15-1-2022, Revised: 29-1-2022, Accepted: 31-1-2022

ABSTRACT

Pharmacovigilance begins from clinical phase and go on throughout the product life- cycle of the medicine.Pharmacovigilance focuses at assessment, detection and prevention of any possible medicine related problems and adverse event, particularly acute adverse event and long term adverse event of medicines, biotic products, herbalism and traditional drugs. In recent times, pharmacovigilance has evolved with amplifying significance to more clinical practice and public health knowledge. The chromatic techniques used in pharmacovigilance are active surveillance, passive surveillance, stimulated reporting, targeted clinical investigation, comparative observational studies, descriptive studies. In order to keep up the demands and preservation of case's health the new developments in pharmacovigilance is essential also, pharmacovigilance techniques can also be used to identify that which cases can develop ADRs and how they can develop ADR and for this the most important factor will be the use of the cases as a source of information in the field of pharmacovigilance.

Pharmacovigilance plays a critical part in assuring that cases enter safe medicines. Our knowledge of a medicine's adverse responses can be increased by chromatic means, including spontaneous reporting,

intensive monitoring and database studies. New processes, both at a directorial and a scientific position, are being developed with the goal of strengthening pharmacovigilance. On a directorial position, these include tentative approval and threat management plans; on a scientific position, clarity and increased patient involvement are two important essentials. Ideal To review and talk over chromatic aspects of pharmacovigilance, including new methodological developments.

KEYWORDS: Pharmacovigilance, Active surveillance, Adverse events, Drug safety, Intensive monitoring, Spontaneous reporting.

INTRODUCTION:

Pharmacovigilance focuses at assessment, detection and prevention of any possible medicine related problems and adverse event, particularly acute adverse event and long term adverse event of medicines, biotic products, herbalism and traditional drugs. It plays an important part in decision-making in pharmacotherapeutics[l ,2].

It promotes safe and rational use of medicines by Enhancing the timely discovery of earlier unknown ADRs and medicine relations. Detecting threat factors that develop ADRs.Assessment of quantitative aspects of benefit/ threat analysis. Circulating information to enhance the prescription and regulation of medicine[3].

Pharmacovigilance begins from clinical phase and go on throughout the product life- cycle of the medicine[2].



In recent times, pharmacovigilance has evolved with amplifying significance to more clinical practice and public health knowledge. But now a days, lots of challenges are faced in the field of pharmacovigilance to establish a better healthcare system in this world.

Methods of Pharmacovigilance:



1.Active Surveillance

Active surveillance, in discrepancy to unresistant surveillance, seeks to ascertain fully the number of adverse events via a non stop pre-organised process. An illustration of active surveillance is the follow-up of cases treated with a particular medicine through a threat Operation program. Cases who fill a tradition for this medicine may be asked to complete a brief check form and give authorization for after contact. In general, it's further doable to get comprehensive data on Individual adverse event reports through an active surveillance system than through a unresistant reporting system.

Sentinel Spots

Active surveillance can be achieved by reviewing medical records or canvassing cases and/ or croakers in a sample of guard spots to insure complete and accurate data on reported adverse events from these spots. The named spots can give information, similar as data from specific patient Groups, that would not be available m a unresistant robotic reporting system. Further, information on the use of a medicine, similar as abuse, can be targeted at named guard spots. Some of the major sins of guard spots are problems with selection bias, small figures of cases, and increased costs. Active surveillance with guard spots is most Effective for those medicines used substantially in institutional settings similar as hospitals, nursing homes, haemodialysis centres, etc. Institutional settings can have a lesser frequency of use for certain medicine products and can give an structure for devoted reporting. In addition, automatic discovery of abnormal laboratory values from motorized laboratory reports m certain clinical settings can give an effective active surveillance system. Ferocious monitoring of guard spots can also be helpful in relating pitfalls among cases taking orphan medicines.

Medicine Event Monitoring

Medicine event monitoring is a system of active pharmacovigilance surveillance. In medicine event monitoring, cases might be linked from electronic tradition data or automated health insurance claims. A follow-up questionnaire can also be transferred to each defining croaker or case at pre-specified intervals to gain outgrowth information. Information on patient demographics, suggestion for treatment, duration of

remedy (including launch dates), lozenge, clinical events, and reasons for termination can be included in the questionnaire.

Limitations of medicine event monitoring can include poor croaker and patient response rates and the directionless nature of data collection, which can obscure important signals. In addition, conservation of patient confidentiality might be a concern. On the other hand, more detailed information on adverse events from a large number of croakers and/ or cases might be collected. Registries

A registry is a list of cases presenting with the same characteristic (s). This specific can be a complaint (complaint registry) or a specific exposure (medicine registry). Both types of registries, which exclusively differ by the type of patient data of claim, can collect a battery of information utilizing standardised questionnaires in a prospective fashion. Disease registries, similar as registries for blood dyscrasias, severe cutaneous responses, or natural deformations can help collect data on medicine exposure and other factors associated with a clinical condition. A complaint registry might also be used as a base for a case- control study comparing the medicine exposure of cases linked from the registry and controls named from either cases with another condition within the registry, or cases outside the registry. Exposure(medicine) registries address populations exposed to medicines of interest (e.g., registry of rheumatoid arthritis cases exposed to natural curatives) to determine if a medicine has a special impact on this group of cases. Some exposure (medicine) registries address medicine exposures in specific populations, similar as pregnant women. Cases can be followed over time and included in a cohort study to collect data on adverse events using standardised questionnaires. Single cohort studies can measure prevalence, but, without a comparison group, can not give evidence of association. Still, they can be useful for signal modification, particularly for rare issues. This type of registry can be veritably precious when examining the safety of an orphan medicine indicated for a specific condition [1,7].

2.Stimulated Reporting

Several techniques have been used to encourage and grease reporting by health professionals in specific situations (e.g., in- sanatorium settings) for new products or for limited time ages. Similar techniques include on- line reporting of adverse events and methodical stimulation of reporting of adverse events grounded on a pre-designed system. Although these styles have been shown to Ameliorate reporting, they aren't devoid of the limitations of unresistant surveillance, especially picky reporting and deficient information. During the early post-marketing phase, companies might laboriously give health professionals with safety information, and at the same time encourage conservative use of new products and the submission of spontaneous reports when an adverse event is linked. A plan can be elaborated before the product is launched (e.g., through point visits by company representatives, by direct mailings or faxes,etc.). Stimulated adverse event reporting in the early post-marketing phase can lead companies to notify healthcare professionals of new curatives and give safety information beforehand in use by the general population (e.g., Beforehand Post-marketing Phase Alert, EPPV in Japan). This should be regarded as a form of robotic event reporting, and therefore data attained from

stimulated reporting can not be used to induce accurate prevalence rates, but reporting rates can be estimated 71.

3.Passive Surveillance

Spontaneous Reports

A spontaneous report is an unasked communication by healthcare professionals or consumers to a company, nonsupervisory authority or other organisation (e.g., WHO, Regional Centres, Bane Control Centre) that describes one or further adverse medicine responses in a case who was given one or further medicinal products and that doesn't decide from a study or any systematized data collection scheme. Spontaneous reports play a major part in the identification of safety signals once a medicine is retailed. In numerous cases, a company can be advised to rare adverse events that weren't detected in earlier clinical trials or other pre-marketing studies. Robotic reports can also give important information on at- threat groups, threat factors, and clinical features of known serious adverse medicine responses. Caution should be exercised in assessing spontaneous reports, especially when comparing medicines. The data accompanying spontaneous reports are Frequently deficient, and the rate at which cases are reported is dependent on numerous factors including the time since launch, pharmacovigilance- related nonsupervisory exertion, media attention, and the suggestion for use of the medicine[5,6].

Methodical Styles for the Evaluation of Spontaneous Reports More Lately, methodical styles for the discovery of safety signals from spontaneous reports have been used. Numerous of these ways are still in development and their utility for relating safety signals is being estimated. These styles include the computation of the commensurable reporting rate, as well as the use of Bayesian and other ways for signal Discovery. Data booby-trapping ways have also been used to examine medicine- medicine relations. Data mining ways should always be used in confluence with, and not in place of, analyses of single case reports. Data booby-trapping ways grease the evaluation of robotic reports by using statistical styles to descry implicit signals for farther evaluation. This tool doesn't quantify the magnitude of threat, and caution should be exercised when comparing drugs. Further, when using data mining ways, consideration should be given to the threshold established for detecting signals, since this will have counteraccusations for the perceptivity and particularity of the system (a high threshold is associated with high particularity and low perceptivity). Confounding factors that impact spontaneous adverse event reporting aren't removed by data mining. Results of data mining should be interpreted with the knowledge of the sins of the spontaneous reporting system and, more specifically, the large differences in the ADR reporting rate among different medicines and the numerous implicit impulses essential in spontaneous reporting. All signals should be estimated recognising the possibility of false cons. In addition, the absence of a signal doesn't mean that a problem doesn't live[4,7].

Case Series

Series of case reports can give substantiation of an association between a medicine and an adverse event, but they're generally more useful for generating suppositions than for vindicating an association between medicine exposure and outgrowth. There are certain distinct adverse events known to be associated more constantly with medicine remedy, similar as anaphylaxis, aplastic anemia, poisonous epidermal necrolysis and Stevens-Johnson Pattern. Thus, when events Similar as these are spontaneously reported, guarantors should place further emphasis on these reports for detailed and rapid-fire follow-up.

4.Comparative Observational Studies:

Traditional epidemiologic styles are a crucial element in the evaluation of adverse events. There are a number of experimental study designs that are useful in validating signals from robotic reports or case series. Major types of these designs are cross-sectional studies, case- control studies, and cohort studies (both retrospective and prospective).

Cross-Sectional Study (Check) Data collected on a population of cases at a single point in time (or interval of time) anyhow of exposure or complaint status constitute across-sectional study. These types of studies are primarily used to gather data for checks or for ecological analyses. The major debit of cross-sectional studies is that the temporal relationship between exposure and outgrowth can not be directly addressed. These studies are stylish used to examine the frequency of a complaint at one time point or to examine trends over time, when data for periodical time points can be captured. These studies can also be used to examine the crude association between exposure and outgrowth in ecologic analyses. Cross-sectional studies are stylish utilised when exposures don't change over time. Case- Control Study

In a case- control study, cases of complaint (or events) are linked. Controls, or cases without the complaint or event of interest, are also named from the source population that gave rise to the cases. The controls should be named in such a way that the frequency of exposure among the controls represents the frequency of exposure in the source population. The exposure status of the two groups is also compared using the odds rate, which is an estimate of the relative threat of complaint in the two groups. Cases can be linked from an being database or using data collected specifically for the purpose of the study of interest. If safety information is sought for special populations, the cases and controls can be separate according to the population of interest(the senior, children, pregnant women,etc.). For rare adverse events, being large population- grounded databases are a useful and effective means of furnishing demanded medicine exposure and medical outgrowth data in a fairly short period of time. Case- control studies are particularly useful when the thing is to probe whether there is an association between a medicine (or medicines) and one specific rare adverse event, as well as to identify Threat factors for adverse events. Threat factors can include conditions similar as renal and hepatic dysfunction, that might modify the relationship between the medicine exposure and the adverse event. Under specific conditions, a case- control study can give the absolute prevalence rate of the event. If all cases

of interest (or a well- defined bit of cases) in the catchment area are captured and the bit of controls from the source population is known, an prevalence rate can be calculated.

Cohort Study

In a cohort study, a population-at- threat for the complaint (or event) is followed over time for the Circumstance of the complaint (or event). Information on exposure status is known throughout the follow-up period for each case. A case might be exposed to a medicine at one time during follow-up, but non-exposed at another time point. Since the population exposure during follow-up is known, prevalence rates can be calculated. In numerous cohort studies involving medicine exposure, comparison cohorts of interest are named on the base of medicine use and followed over time. Cohort studies are useful when there's a need to know the prevalence rates of adverse events in addition to the relative pitfalls of adverse events. Multiple adverse events can also be delved using the same data source in a cohort study. Still, it can be delicate to Novitiate sufficient figures of cases who are exposed to a medicine of interest (similar as an orphan medicine) or to study veritably rare issues. Like case- control studies, the identification of cases for cohort studies can come from large automated databases or from data collected specifically for the study at hand. In addition, cohort studies can be used to examine safety issues in special populations (the senior, children, cases with co-morbid conditions, pregnant women) through over-sampling of these cases or by stratifying the cohort if sufficient figures of cases live. There are several automated databases available for pharmacoepidemiologic studies. They include databases which contain automated medical records or automated account/ billing systems. Databases that are created from account/ billing systems might be linked to drugstore claims and medical claims databases. These datasets might include millions of cases. Since they're created for executive or billing purposes, they might not have the detailed and accurate information demanded for some exploration, similar as validated Individual information or laboratory data. Although medical records can be used to ascertain and validate test results and medical judgments, one should be conscious of the sequestration and confidentiality regulations that apply to patient medical records[10].



5.Targeted Clinical Investigations

When significant pitfalls are linked from pre-approval clinical trials, further clinical studies might be called for to -organised the medium of action for the adverse response. In some cases, pharmacodynamics and pharmacokinetic studies might be conducted to determine whether a particular dosing instruction can put cases at an increased threat of adverse events. Inheritable testing can also give suggestions about which group of cases might be at an increased threat of adverse responses. Likewise, grounded on the pharmacological parcels and the anticipated use of the medicine in general practice, conducting specific studies to probe implicit Medicine- medicine relations and food- medicine relations might be called for. These studies can include population pharmacokinetic studies and medicine attention monitoring in cases and normal levies. Occasionally, implicit pitfalls or unlooked-for benefits in special populations might be linked frompre-approval clinical trials, but can not be completely quantified due to small sample sizes or the rejection of subpopulations of cases from these clinical studies. These populations might include the senior, children, or cases with renal or hepatic complaint. Children, the senior, and cases with co-morbid conditions might metabolise medicines else than cases Generally enrolled in clinical trials. Farther clinical trials might be used to determine and to quantify the magnitude of the threat (or benefit) in similar populations. To interpret the benefit threat profile of a medicine outside of the formal/ traditional clinical trial setting and/ or to completely quantify the threat of a critical but fairly rare adverse event, a large simplified trial might be conducted. Cases enrolled in a large simplified trial are generally randomized to avoid selection bias. In this type of trial, however, the event of interest will be concentrated to insure a accessible and practical study. One limitation of this system is that the outgrowth measure might be too simplified and this might have an impact on the quality and ultimate utility of the trial. Large, simplified trials are also resource-ferocious [8].

6.Descriptive Studies

Illustrative studies are an important component of pharmacovigilance, although not for the discovery or verification of adverse events associated with medicine exposures. These studies are primarily used to gain the background rate of outgrowth events and/ or establish the frequency of the use of medicines in specified populations.

Natural History of Disease

The wisdom of epidemiology firstly concentrated on the natural history of complaint, including the characteristics of diseased cases and the distribution of complaint in named populations, as well as estimating the prevalence and frequency of implicit issues of interest. These issues of interest now include a description of complaint treatment patterns and adverse events. Studies that examine specific aspects of adverse events, similar as the background prevalence rate of or threat factors for the adverse event of interest, can be used to help in putting Robotic reports into perspective. For illustration, an epidemiologic study can be conducted

using a complaint registry to understand the frequency at which the event of interest might do in specific groups, similar as cases with attendant ails.

Medicine Utilisation Study

Medicine utilisation studies (DUS) describe how a medicine is retailed, specified, and used in a population, and how these factors impact issues, including clinical, social, and profitable issues. These studies give data on specific populations, similar as the senior, children, or cases with hepatic or renal dysfunction, frequently stratified by age, gender, attendant Drug, and other characteristics. DUS can be used to discover if a product is being used in these populations. From these studies denominator data can be developed for use in determining rates of adverse medicine responses. DUS have been used to describe the effect of nonsupervisory conduct and media attention on the use of medicines, as well as to develop estimates of the profitable burden of the cost of medicines. DUS can be used to examine the relationship between recommended and factual clinical practice. These studies can help to determine whether a medicine has the eventuality for medicine abuse by examining whether cases are taking raising cure rules or whether there's substantiation of unhappy reprise defining. Important limitations of these studies can include a lack of clinical outgrowth data or information of the suggestion for use of a product

Recent Development

Pharmacovigilance and the styles used need to continue to develop in order to keep up with the demands of society. In recent times, three publications have been of utmost significance in terms of furnishing guidance on the future of pharmacovigilance. The first is the Erice Declaration on translucency, which was published in 1997 [9]. In this protestation, pharmacovigilance experts from each over the world, representing different sectors, emphasise the part of communication in medicine safety with the following statements Medicine safety information must serve the health of the public Education in the applicable use of medicines, including interpretation of safety information, is essential for the public at large, as well as for health care providers All the substantiation demanded to assess and understand pitfalls and benefits must be openly available Every country needs a system with independent moxie to insure that safety information on all available medicines is adequately collected, impartially estimated and made accessible to all Innovation in medicine safety monitoring needs to insure that arising problems are instantly recognised and efficiently dealt with, and that information and results are effectively communicated It's believed that these factors will help pitfalls and benefits to be assessed, explained and acted upon openly and in a spirit that promotes general confidence and trust. This protestation was followed in 2007 by the Erice Manifesto for global reform of the safety of drugs in patient care[ll]. The Erice Manifesto specifies the chal lenges which must be addressed to insure the continuing development and utility of the wisdom, in particular The active involvement of cases and the public in the core debate about the pitfalls and benefits of drugs, and in opinions about their own treatment and health The development of new ways of collecting, analysing and communicating information about the

safety and effectiveness of drugs; open discussion about it and the opinions which arise from it The pursuit of learning from other disciplines about how pharmacovigilance styles can be bettered, alongside wide-ranging professional, sanctioned and public collaboration The creation of purposeful, coordinated, worldwide support amongst politicians, officers, scientists, clinicians, cases and the general public, grounded on the provable benefits of pharmacovigilance to public health and patient safety The third composition that has had a profound impact on how pharmacovigilance should work in the future is the composition published in 2002 by Waller and Evans in which they give their view on the unborn conduct of pharmacovigilance. The crucial values that should bolster pharmacovigilance are excellence (defined as the stylish possible result), the scientific system and translucency. The paper defines five rudiments that are considered to be essential for achieving excellence. Three of these are process- acquainted stylish substantiation, robust scientific decision-timber and effective tools to deliver protection of public health. The other two rudiments, scientific development and inspection, bolster these processes, recognising that excellence can not be achieved simply by process[14].

Methodological developments

Transparency:

The Erice Declaration[12], as well as Waller and Evans[14], stated that translucency is important for the future of pharmacovigilance. In the last many times translucency around ADRs has increased. The enrolment of clinical trials will allow the necessary shadowing of trials to insure full and unprejudiced reporting for public benefit [13]. A number of countries, have made their databases containing the data from the robotic reporting system freely available to the public.

Conditional approval:[161

Both the FDA report and the report from the European Union described before emphasise that compliance by selling authorisation holders needs to be bettered when it comes to fresh post marketing studies. A possible result to this problem would be a time- limited tentative blessing, which would place pressure on the manufacturers to conduct and report fresh safety studies.

Within the European Union, the EMEA has introduced a tentative marketing authorisation. The Committee for Medicinal Products for Human Use (CHMP) delivers a tentative marketing authorisation for products where there's a specific patient need. Exemplifications include products for seriously enervating or life-hanging conditions, medic inal products to be used in exigency situations in response to public pitfalls and products designated as orphan medicinal products. A tentative marketing authorisation is granted in the absence of comprehensive clinical data pertaining to the safety and efficacy of the medicinal product. Still, a number of criteria have to be met including.

1. A positive threat- benefit balance of the product

2. Likeliness that the aspirant will be in a position to give the comprehensive clinical data
3. Unmet medical requirements being fulfilled
4. The benefit of the immediate vacuity of the medicinal product to public health overbalancing the threat essential in the absence of fresh data

Tentative marketing authorisations are valid for 1 time, on a renewable base. The holder is needed to complete ongoing studies or to conduct new studies with the ideal of attesting that the threat benefit balance is positive. In addition, specific scores may be assessed in relation to the collection of pharmacovigilance data. The authorisation isn't intended to remain tentative indefinitely. Rather, once the missing data are handed, it should be possible to replace it with a formal marketing authorisation. The permission of a tentative marketing authorisation will allow drugs to reach cases with unmet medical requirements before than might else be the case and will insure that fresh data on a product are developed, submitted, assessed and acted upon.

Risk Management

Another step in a further pro-activepost-marketing eavesdrop shaft is the preface of threat operation plans (RMPs) [19]. Similar RMPs are being set up in order to identify. characterise, help or minimise threat relating to medicinal products, including the evaluation of the effectiveness of those interventions. A RMP may need to be submitted at any time in a product's life cycle, for illustration, during both the pre-authorisation and post-authorisation phases. A RMP is needed for all new active substances, significant changes in established products (e.g. new form/ route of administration), established products introduced to new populations, significant new suggestions or when an unanticipated hazard is linked.

The EU Risk Management Plan consists of two corridor the first part contains a' safety

specification and a pharmaco alert plan ‘and the alternate part contains an evaluation of the need for threat minimisation conditioning and, if necessary, a threat minimization plan. The safety specification contains a summary of what's known and what's not. known about the safety of the product. This specification encompasses the important linked threat and any information and outstanding safety questions which warrant further disquisition in order to upgrade the understanding of benefit — threat during the post-authorisation period. A threat minimization plan is only needed in circumstances where the standard information provision, by means of a drug's summary of product characteristics, is considered shy. Inadequate patient information splint-lets or shy labelling of the drug are additional reasons for drawing up a threat minimization plan. Where a risk minimization plan is considered necessary, both routine and fresh conditioning are to be included. Some safety concerns may have further than one threat minimisation exertion, each of which should be estimated for effectiveness. Many RMPs have formerly been established; still, to date, no quantitative or qualitative reports have been released by the EMEA. Information to the public about RMPs has also been scarce.

However, they need to be made public and easily accessible to scientists, professionals and cases If RMPs are to take an important place in pharmacovigilance

Involvement of Patients:

Another important development is the recognition of the patient as an important player in pharmacovigilance. Patients are the druggies of medicines, and it's their use of a drug in a safe manner is the ultimate thing of pharmaco- alert conditioning. In an adding number of countries patients are now allowed to report ADRs to the spontaneous reporting system. The European Commission acknowledges the part of the case in spontaneous reporting[15]. Cases and patient organisations are becoming decreasingly more involved in pharmacovigilance- shaft, especially when it comes to threat communication [9, 17].

After introducing patient reporting in the spontaneous reporting scheme in 2004[18],the Netherlands Pharmacovigilance Centre Lareb took patient reporting one step further and introduced, in 2006, an ferocious monitoring programme using cases as a source of information. The Lareb ferocious monitoring programme, follows the prescription- event monitoring methodology in that patients are linked on the base of conventions. Eligible patients are linked in their apothecaries when they come and pick up for the first time the medicine understudy. Patients can register at the website, and during a certain period of time they will admit questionnaires asking them about adverse events. The system is totally web- grounded; accordingly, questionnaires can be transferred via e-mail to sharing cases at different points, allowing the collection of longitudinal data. The high position of automation also allows a rapid-fire collection and analysis of data [20].

Conclusion:

PV remains a dynamic part of the clinicians and the general population. After the appearance of these adverse medicines goods, it's truly essential that these are reported timely and analysed. Not only the doctors should be conscious of the PV programme but the cases themselves should be made conscious of this so self-reporting is increased and the burden on the clinicians is also reduced. India is still in the growing phase of PV and further reporting is necessary to reach the world's standard of reporting these adverse events to give effective medicine use in children's and pregnant women which is one of the most vulnerable populations of all. The PV programme must be suitable to identify these adverse events timely in the coming times with the help of clinicians, cases, and the pharmaceutical industry to help shape the safety of cases themselves.

There are various methods of collecting data in pharmacovigilance such as Active surveillance, Stimulated reporting, Passive surveillance, Comparative observational studies, Targeted clinical investigations, Descriptive studies.

Recently various methods are developed for ease of pharmacovigilance studies which includes Translucency, Conditional approval, Risk management plans, Involvement Of Patients.

REFERENCES:

[1] Ronald H.B Meyboom, Antoine C.G Egberts, Frank W.J Gribnau, Yechiel A. Hekster, Drugsafety 1999 Dec 21 (6) 429-447, 0114-5916/99/0012-0429/S09.50/0.

[2] WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003. WHO/EDM/2000.1

[3] JE Campbell, M Gossell-WiIliams, MG Lee, West Indian Med J 2014; 63 (7): 771, DOI: 10.7727/wimj.2013.251

[4] Peter R. Arlett, Xavier Kurz, Drug Discovery Today: Technologies, Innovative methods in drug regulatory sciences vol. 8, No. 1 2011, DOI: 10.1016/j.ddtec.2011.03.003.

[5] van Grootheest K, Olsson S, Couper M et al. (2004) Pharmacists'role in reporting adverse drug reactions in an internationalperspective. Pharmacoepidemiol Drug Saf 13:457—464

[6] van Grootheest AC, Passier JL, van Puijenbroek EP (2005)Direct reporting of side effects by the patient: favourable experience in the first year. Ned Tijdschr Geneeskd 149:529—533

[7] Mudasir Maqbool, Mohmad Amin Dar, Shafiqa Rasool, Ahsan Ullaha Bhat, Mohammad Ishaq Geer, Journal of Drug Delivery & Therapeutics, 2019; 9(2-s):543-548.

[8] Kumar Sumit, Baldi Ashish, Journal of Drug Delivery & Therapeutics; 2013, 3(4), 237, ISSN: 2250-1177

[9] Hugman B (2006) The Erice declaration: the critical role of communication in drug safety. Drug Saf 29:91-93

[10] Dr. Alka Sawarkar, Dr. RK Sharma, Dr. Vidhi Gautam, Dr. K Shramankar and Dr. Neelam Dinodia, The Pharma Innovation Journal 2019; 8(8): 84-92, ISSN (E): 2277- 7695.

[11] Adis International (2007) The Erice Manifesto: for globalreform of the safety of medicines in patient care. Drug Saf 30: 187—190

[12] Hugman B (2006) The Erice declaration: the critical role of communication in drug safety. Drug Saf 29:91-93

[13] Sim l, Chan AW, Gulmezoglu AM et al. (2006) Clinical trialregistration: transparency is the watchword. Lancet 367: 1631—1633

[14] Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12: 17—29

[15] European Commission Enterprise and Industry Directorate-general(2007) Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance. European Commission Enterprise and Industry, Brussels

[16] European Medicines Agency (EMEA) (2005) Guideline on procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to article 14(8) of regulation (EC) NO 726/2004 Available at http://www.emea.europa.eu/pdfs/human/euleg/35798105en.pdf. Cited 18 Dec 2007

[17] van Grootheest K, de Graaf L, de Jong-van den Berg LT (2003) Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf26:211

[18] de Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K (2008) Adverse drug reaction reporting by patients in the Netherlands: Three years of experience. Drug Saf 6:515-524

[19] European Medicines Agency (EMEA) (2005) Guideline on risk management systems for medicinal products for human use. Available at http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf. Cited 18 Dec 2007

[20] Härmark L, Kabel JS, van Puijenbroek EP, van GrootheestAC (2006) Web-based intensive monitoring, a new patient based tool for early signal detection (abstr). Drug Saf 29:911—1010